LENZ Therapeutics (LENZ) Free Cash Flow: 2022-2023
Historic Free Cash Flow for Therapeutics (LENZ) over the last 2 years, with Dec 2023 value amounting to -$21.0 million.
- Therapeutics' Free Cash Flow rose 10.58% to -$21.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$60.4 million, marking a year-over-year increase of 36.12%. This contributed to the annual value of -$59.9 million for FY2024, which is 0.91% up from last year.
- According to the latest figures from Q4 2023, Therapeutics' Free Cash Flow is -$21.0 million, which was down 60.22% from -$13.1 million recorded in Q3 2023.
- Therapeutics' 5-year Free Cash Flow high stood at -$12.8 million for Q1 2023, and its period low was -$24.5 million during Q1 2022.
- For the 2-year period, Therapeutics' Free Cash Flow averaged around -$19.4 million, with its median value being -$22.1 million (2022).
- Data for Therapeutics' Free Cash Flow shows a peak YoY surged of 47.77% (in 2023) over the last 5 years.
- Therapeutics' Free Cash Flow (Quarterly) stood at -$23.4 million in 2022, then grew by 10.58% to -$21.0 million in 2023.
- Its last three reported values are -$21.0 million in Q4 2023, -$13.1 million for Q3 2023, and -$13.5 million during Q2 2023.